Monoclonal antibodies and therapeutics;Anticorps monoclonaux et thérapeutique

Pathologie Biologie

Volumn 52, Issue 6, 2004, Pages 351-364

  Desgranges, C ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Anticorps monoclonaux; Immunoth rapie passive; Monoclonal antibodies; Passive immunotherapy; Therapeutic; Th rapeutique

Indexed keywords

ABCIXIMAB; ALEMTUZUMAB; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; EDRECOLOMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; OKT 3; PALIVIZUMAB; RADIOISOTOPE; RITUXIMAB; TRASTUZUMAB;

ANTIBODY ENGINEERING; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BACTERIAL CELL; BACULOVIRUS; BINDING AFFINITY; BIOTECHNOLOGY; CANCER CHEMOTHERAPY; CARCINOMA; CHIMERA; CLINICAL TRIAL; DRUG INDUSTRY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GENETIC RECOMBINATION; GRAFT REJECTION; HUMAN; IMMUNE SYSTEM; IMMUNOTHERAPY; INFECTION; INSECT CELL; LYMPHOCYTE CULTURE; MAMMAL CELL; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; ONCOLOGY; PHAGE DISPLAY; REVIEW; SCALE UP; TRANSGENIC ANIMAL; TRANSGENIC MOUSE; TRANSGENIC PLANT; YEAST CELL;

EID: 3142695491     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2003.09.017     Document Type: Short Survey

References (104)

1. Ehrlich P. On immunity: with special reference to cell life. Proc R Soc Lond. 66:1900;424-448
2. Keller M.A., Stiehm E.R. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev. 4:2000;602-614
3. Tonegawa S., Brack C., Hozumi N., Pirrotta V. Organization of immunoglobulin genes. Cold Spring Harb Symp Quant Biol. 42:1978;921-931
4. Seidman J.G., Leder P. The arrangement and rearrangement of antibody genes. Nature. 276:1978;790-795
5. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:1975;495-497
6. Barski G., Sorieul S., Cornefert F. Production dans des cultures in vitro de deux souches cellulaires en association de cellules de caractère hybride. C R Acad Sci (Paris). 251:1960;1825-1827
7. Waldmann T.A. Immunotherapy: past, present and future. Nat Med. 9:2003;269-277
8. Miller R.A., Maloney D.G., Warnke R., Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 306:1982;517-522
9. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N. Engl. J; Med. 313:1985;337-342
10. Schroff R.W., Foon K.F., Beatty S.M., Oldham R.K., Morgan A.C.J. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. 45:1985;879-885
11. Hudson P.J., Souriau C. Engineered antibodies. Nat Med. 9:2003;129-134
12. Morrison S.L., Johnson M.J., Herzenberg L.A., Oi V.T. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A. 81:1984;6851-6855
13. Faulds D., Sorkin E.M. Abciximab (C7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs. 48:1994;583-598. Review
14. Jones P.T., Dear P.H., Foote J., Neuberger M., Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 321:1986;522-525
15. Hale G., Dyer M.J., Clark M.R., Phillips J.M., Marcus R., Riechmann L., et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet. 2:1988;1394-1399
16. Brown P.S.J., Parenteau G.L., Dirbas F.M., Garsia R.J., Goldman C.K., Bukowski M.A., et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci USA. 88:1991;2663-2667
17. Reichmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature. 332:1988;323-327
18. Tempest P.R., Bremmer P., Lambert M., Taylor G. Reshaping a human monoclonal antibody to inhibit respiratory syncytial virus infection. Bio/Technology. 9:1991;266-271
19. Steinitz M., Izak G., Cohen S., Ehrenfeld M., Flechner I. Continuous production of monoclonal rheumatoid factor by EBV-transformed lymphocytes. Nature. 287:1980;443-445
20. Trabaud M.-A., Lery L., Desgranges C. Human monoclonal antibodies with a protective activity against tetanus toxin. Acta Path. Microbiol. Immunol. Scand. 97:1989;671-676
21. Paire J., Monestier M., Rigal D., Martel F., Desgranges C. Human monoclonal antibodies against Rhesus D: identification of Rhesus D antigen. Immunol. Lett. 13:1986;137-141
22. Monjour L., Desgranges C., Ploton I., Alfred C., Karabinis A. Production of Human Monoclonal Antibodies against Asexual Erythrocytic Stages of Plasmodium falciparum. Lancet. 8337:1983;1337-1338
23. Monjour L., Alfred C., Ploton I., Desgranges C., Carnevale P., Mazier D., et al. Human lymphocytes transformed with Epstein-Barr virus produce antibodies against sporozoite stage of Plasmodium falciparum. Lancet. 1:1984;515-516
24. Seigneurin J.M., Desgranges C., Seigneurin D., Paire J., Renversez J.-C., Jacquemont B., et al. Herpes Simplex virus glycoprotein D: human monoclonal antibody produced by bone marrow cell line. Science. 221:1983;173-175
25. Seigneurin J., Desgranges C. Anticorps monoclonaux humains anti-cytomégalovirus. Ann. Med. Interne. 138:1987;343-346
26. Desgranges C., Paire J., Pichoud C., Souche S., Frommel D., Trepo C. High affinity human monoclonal antibodies directed against hepatitis B surface antigen. J. Virol. Methods. 16:1987;281-292
27. Habersetzer F., Fournillier A., Dubuisson J., Rosa D., Abrignani S., Wychowski C., et al. Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties. Virology. 249:1998;32-41
28. Desgranges C., Boyer V., Souche S., Sprecher S., Burny A., Gallo R.C., et al. Monoclonal antibodies to HIV in a non-infected, immunised volunteer. Lancet. i:1988;935-936
29. Boyer V., Broly H., Souche S., Madaule P., Rossier J., Zagury D., et al. Characterization and large production of human monoclonal antibodies against the HIV-1 envelope. Clin. Exp. Immunol. 83:1991;452-459
30. Fraisier C., Ebersold A., Blomberg J., Desgranges C. Primary in vitro immunization with multimeric synthetic peptides of HIV-1 envelope glycoproteins: generation of neutralizing human monoclonal antibodies. J. Immunol. methods. 176:1994;9-22
31. Winter G., Griffiths A.D., Hawkins R.E., Hoogenboom H.R. Making antibodies by phages display technology. Annu rev Immunol. 12:1994;433-455
32. Hoogenboom H.R., Winter G. Bypassing immunisation: human antibodies from synthetic repertoires of germ line VH-gene segments rearranged in vitro. J Mol Biol. 227:1992;381-388
33. Yokota T., Milenic D.E., Whitlow M., Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52:1992;3402-3408
34. Hexham J.M., Dudas D., Hugo R., Thompson J., King V., Dowling C., et al. Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins. Mol Immunol. 38:2001;397-408
35. Helguera G., Morrison S.L., Penichet M.L. Antibody-cytokine fusion proteins: harnessing the combined power of cytokines and antibodies for cancer therapy. Clin Immunol. 105:2002;233-246. Review
36. Hanes J., Schaffitzel C., Knappik A., Pluckthun A. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat. Biotechnol. 18:2000;1287-1292
37. Reisner Y., Dagan S. The Trimera mouse: generating human monoclonal antibodies and an animal model for human diseases. Trends Biotech. 16:1998;242-246
38. Bruggemann M., Taussig M.J. Production of human antibody repertoires in transgenic mice. Curr opin biotechnol. 8:1997;455-458
39. Neuberger M. Generating high-avidity human Mabs in mice. Nat Biotechnol. 14:1996;826
40. Tomizuka K., Shinohara T., Yoshida H., Uejima H., Ohguma A., Tanaka S., et al. Double trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies. Proc Natl Acad Sci USA. 97:2000;722-727
41. Verma R., Boleti E., George A.J. Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. J. Immunol.Methods. 216:1998;165-181
42. Pluckthun A. Antibody engineering: advances from the use of Escherichia coli expression systems. Biotechnology. 9:1991;545-551
43. Skerra A. Bacterial expression of immunoglobulin fragments. Curr Opin Immunol. 5:1993;256-262
44. Horwitz A.H., Chang C.P., Better M., Hellstrom K.E., Robinson R.R. Secretion of functional antibody and Fab fragment from yeast cells. Proc Natl Acad Sci USA. 85:1988;8678-8682
45. Joosten V., Lokman C., Van Den Hondel C.A., Punt P.J. The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. Microb Cell Fact. 2:2003;1-15
46. Poul M.A., Cerutti M., Chaabihi H., Ticchioni M., Deramoudt F.X., Bernard A., et al. Cassette baculovirus vectors for the production of chimeric, humanized, or human antibodies in insect cells. Eur J Immunol. 25:1995;2005-2009
47. Jones D., Kroos N., Anema R., Van Montfort B., Vooys A., Van Der Kraats S., et al. High-level expression of recombinant IgG in the human cell line per.c6. Biotechnol Prog. 19:2003;163-168
48. Stoger E., Sack M., Fischer R., Christou P. Plantibodies: applications, advantages and bottlenecks. Curr Opin Biotechnol. 13:2002;161-166
49. Ma J., Hiatt A., Hein M., Vine N., Wang F., Stabila P., et al. Generation and assembly of secretory antibodies in plants. Science. 268:1995;716-719
50. Fiedler U., Phillips J., Artsaenko O., Conrad U. Optimization of scFv antibody in transgenic plants. Immunotechnology. 3:1997;205-216
51. Chargelegue D., Vine N.D., van Dolleweerd C.J., Drake P.M., Ma J.K. A murine monoclonal antibody produced in transgenic plants with plant-specific glycans is not immunogenic in mice. Transgenic Res. 9:2000;187-194
52. Bakker H., Bardor M., Molthoff J.W., Gomord V., Elbers I., Stevens L.H., et al. Galactose-extended glycans of antibodies produced by transgenic plants. Proc Natl Acad Sci USA. 98:2001;2899-2904
53. Emlay D. Regulatory considerations in a changing environment. Hood E.E., Howard J. Plants as factories for Proteins Production. 2002;175-180 Kluwer Academic, Dordrecht
54. Houdebine L.M. Antibody manufacture in transgenic animals and comparaisons with other systems. Curr Opin Biotechnol. 13:2002;625-629
55. Kuroiwa Y., Kasinathan P., Choi Y.J., Naeem R., Tomizuka K., Sullivan E.J., et al. Cloned transchromosomic calves producing human immunoglobulin. Nat Biotechnol. 20:2002;889-894
56. Harvey A.J., Sperksnijder G., Baugh L.R., Morris J.A., Ivarie R. Expression of exogenous protein in the egg white of transgenic chickens. Nature Biotech. 19:2002;396-399
57. Larrick J.W., Yu L., Naftzger C., Jaiswal S., Wycoff K. Production of secretory IgA antibodies in plants. Biomol Eng. 18:2001;87-94
58. Morrow J. Biopharm manufacturing capacities. Genet Eng News. 21:2001;1-85
59. Carter P. Improving the efficacity of antibody-based cancer therapies. Nat Rev Cancer. 1:2001;118-129
60. Gura T. Therapeutic antibodies: magic bullet hit the target. Nature. 417:2002;584-586
61. Souriou C., Huston P.J. Recombinant antibodies for cancer diagnosis and therapty. Expert Opin Biol Ther. 3:2003;305-318
62. Behr T.M., Behe M., Worman B. Trastuzumab and breast cancer. N Eng J Med. 345:2001;995-996
63. Barnes D.M., Miles D.W. Response of metastatic breast cancer to trastuzumab. Lancet. 355:2000;160-161
64. Baselga J., Norton L., Albanell J., Kim Y.M., Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58:1998;2825-2831
65. Yang X.D., Jia X.C., Corvalan J.R.F. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody for cancer therapy. Crit Rev Oncol Hematol. 38:2001;17-23
66. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 349:2003;427-434
67. Punt C.J., Nagy A., Douillard J.Y., Figer A., Skovsgaard T., Monson J., et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet. 360:2002;671-677
68. Cohen Y., Solal-Celigny P., Polliack A. Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance. Haematologica. 88:2003;811-823
69. Grillo-Lopez A.J., Hedrick E., Rashford M. Rituximab: ongoing and future clinical development. Semin Oncol. 29:2002;105-112
70. Hiddemann W., Dreyling M., Unterhalt M. Rituximab plus chemotherapy in follicular and mantle cell lymphomas. Semin Oncol. 30:2003;16-20
71. + primary resistant or relapsed acute myeloid leukemia. Leuk Res. 27:2003;893-897
72. Sievers E.L., Linenberger M. Mylotarg: antibody-targeted chemotherapy comes of age. Curr Opin Oncol. 13:2001;522-527
73. Kumar S., Kimlinger T.K., Lust J.A., Donovan K., Witzig T.E. Expression of CD52 on plasma cells in plasma cell proliferative disorders. Blood. 102:2003;1075-1077
74. Wiseman G.A., Leigh B., Erwin W.D., Sparks R.B., Podoloff D.A., Schilder R.J., et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer. 94:2002;1349-1357
75. Witzig T.E., Gordon L.I., Cabanillas F., Czuczman M.S., Emmanouilides C., Joyce R., et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy vs rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 20:2002;2453-2463
76. Presta L.G., Shields R.L., Namenuk A.K., Hong K., Meng Y.G. Engineering therapeutic antibodies for improved function. Biochem Soc Trans. 30:2002;487-490. Review
77. Acqua W.F., Woods R.M., Ward E.S., Palaszynski S.R., Patel N.K., Brewah Y.A., et al. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol. 169:2002;5171-5180
78. Vincenti F. Interleukin-2 receptor monoclonal antibodies in renal transplantation: current use and emerging regimens. Transplant Proc. 33:2001;3169-3171
79. Hengster P., Pescovitz M.D., Hyatt D., Margreiter R. Roche Study Group. Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Transplantation. 68:1999;310-313
80. Baan C.C., Balk A.H., van Riemsdijk I.C., Vantrimpont P.J., Maat A.P., Niesters H.G., et al. Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation. Transplantation. 75:2003;1704-1710
81. Nashan B., Moore R., Amlot P., Schmidt A.G., Abeywickrama K., Soulillou J.P. CHIB 201 International Study Group. Randomised trial of basiliximab vs placebo for control of acute cellular rejection in renal allograft recipients. Lancet. 350:1997;1193-1198
82. Nair M.P., Nampoory M.R., Johny K.V., Costandi J.N., Abdulhalim M., El-Reshaid W., et al. Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients. Transplant Proc. 33:2001;2767-2769
83. Kobbe G., Schneider P., Rohr U., Fenk R., Neumann F., Aivado M., et al. Treatment of severe steroid refractory acute graft-vs-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant. 28:2001;47-49
84. Martin X., Da Silva M., Virieux S.R., Hadj Aissa A., Buffet R., Tiollier J., et al. Protective effect of an anti-LFA 1 monoclonal antibody (odulimomab) on renal damage due to ischemia and kidney autotransplantation. Transplant Proc. 32:2000;481
85. Zompi S., Tulliez M., Conti F., Leblond V., Gaulard P., Blanche P., et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases. J Hepatol. 32:2000;521-527
86. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol. 2:2002;364-371
87. Andreakos E., Taylor P.C., Feldmann M. Monoclonal antibodies in immune and inflammatory diseases. Curr Opin Immunol. 13:2002;615-620
88. Bell S., Kamm M.A. Antibodies to tumour necrosis factor alpha as treatment for Crohn's disease. Lancet. 355:2000;858-860
89. Braun J., van der Heijde D. Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. Expert Opin Investig Drugs. 12:2003;1097-1109
90. Billiau A.D., Cornillie F., Wouters C. Infliximab for systemic onset juvenile idiopathic arthritis: experience in 3 children. J Rheumatol. 29:2002;1111-1114
91. Gottlieb A.B. Infliximab for psoriasis. J Am Acad Dermatol. 49:2003;S112-S117
92. Robinson R.F., Nahata M.C. Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection. Am J Health Syst Pharm. 57:2000;259-264
93. Pin I., Pilenko C., Bost M. Prevention of respiratory syncytial virus infection by SYNAGIS (palivizumab) Review. Allerg Immunol (Paris). 34:2002;371-374
94. Hamilton A.A., Manuel D.M., Grundy J.E., Turner A.J., King S.I., Adair J.R., et al. A humanized antibody against human cytomegalovirus (CMV) gp UL75 (gH) for prophylaxis or treatment of CMV infections. J Infect Dis. 176:1997;59-68
95. De Logu A., Williamson R.A., Rozenshteyn R., Ramiro-Ibanez F., Simpson C.D., Burton D.R., et al. Characterization of a type-commun human recombinant monoclonal antibody to herpes simplex virus with high therapeutic potential. J Clin Microbiol. 36:1998;3198-3204
96. Zeitlin L., Olmsted S.S., Moench T.R., Co M.S., Martinell B.J., Paradkar V.M., et al. A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes. Nat Biotechnol. 16:1998;1361-1364
97. Galun E., Eren R., Safadi R., Ashour Y., Terrault N., Keeffe E.B., et al. Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties. Hepatology. 35:2002;673-679
98. Allander T., Drakenberg K., Beyene A., Rosa D., Abrignani S., Houghton M., et al. Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. J Gen Virol. 81:2000;2451-2459
99. Ruprecht R.M., Ferrantelli F., Kitabwalla M., Xu W., McClure H.M. Antibody protection: passive immunization of neonates against oral AIDS virus challenge. Vaccine. 21:2003;3370-3373
100. Veazey R., Shattock R., Pope M., Kirijan J.C., Jones J., Hu Q., et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med. 9:2003;343-346
101. Casadevall A. Antibodies for defense against biological attack. Nature Biotech. 20:2002;114
102. Maynard J.A., Maassen C.B.M., Leppla S.H., Brasky K., Patterson J.L., Iverson B.L., et al. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nature Biotech. 20:2002;597-601
103. Nowakowski A., Wang C., Powers D.B., Amersdorfer P., Smith T.J., Montgomery V.A., et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci USA. 99:2002;11346-11350
104. Parren P.W.H.I., Geisbert T.W., Maruyama T., Jahrling P.B., Burton D.R. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol. 76:2002;6408-6412